A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
NCT ID: NCT06995573
Last Updated: 2025-05-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
90 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-06-30
Study Completion Date
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
NCT01009255
Alzheimer's Disease
COMPLETED
PHASE2
Study of LM11A-31-BHS in Mild-moderate AD Patients
NCT03069014
Mild to Moderate Alzheimer's Disease
COMPLETED
PHASE1/PHASE2
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
NCT00810147
Alzheimer's Disease
COMPLETED
PHASE2
A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])
NCT01496170
Alzheimer's Disease
COMPLETED
PHASE1
Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
NCT00948259
Alzheimer´s Disease
COMPLETED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
NSC001 is an orally administered small molecule rigid cholinergic agonist that has a high selectivity for M1 muscarinic receptors (MI), designed to improve cognitive and behavioral function in patients with Alzheimer's Disease (AD). The primary pharmacology available for NSC001 from preclinical models and studies in healthy volunteers provides a compelling rationale for the evaluation of the safety and tolerability of this compound in patients with mild to moderate AD and for the investigation of NSC001 effects on cognitive function and behavior in such patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alzheimer Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
40 mg QD of NSC001
Group Type
EXPERIMENTAL
NSC001
Intervention Type
DRUG
rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor
Arm 2
40 mg QD of NSC001 + 20 mg of Trospium
Group Type
EXPERIMENTAL
NSC001
Intervention Type
DRUG
rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor
Arm 3
Placebo: with or without 20 mg of Trospium
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
matching placebo to NSC001
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NSC001
rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor
Intervention Type
DRUG
Placebo
matching placebo to NSC001
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants and competent trial partner/caregiver are willing and able to give signed informed consent for participation in the trial including compliance with the requirements and restrictions according to local regulations for the trial Informed Consent Form (ICF). Signed informed consent by the patient (examined and verified to be mentally capable by an independent physician/ neurologist) prior to the initiation of any study specific procedure.
* Must have an informant or trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant (at least 10 hours/week), who is considered reliable by the Investigator in providing support to the participant to ensure compliance with the trial intervention, including the proper and consistent intake of the study medication, who can accompany the participant to trial visits and help with protocol procedures, and who is also able and willing to provide input for completing the caregiver scales and sign the caregiver consent form.
* Male or female aged 50 to 85 years, inclusive at the time of consent.
* Female trial participants must be post-menopausal for at least 2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months prior to screening.
* Male trial participants with partners who are women of childbearing potential (WOCBP) must agree to use a reliable means of contraception (e.g., minimum condom + spermicide) during the trial and 6 months after discontinuing the trial intervention
* Participants who have a clinical diagnosis of AD, which falls into the stages of mild to moderate dementia (Stage 4 to 5) according to the utilized by the NIA-AA 2018 criteria at screening.
* Patients who show CSF biomarker data supporting the diagnosis of AD measured within the last 3 years or patients with a positive Amyloid Pet Scan within the last 3 years or have a test on p-tau217 in plasma indicating brain amyloid positivity will qualify for the study. Plasma pTau217 concentration of ≥ 2.0 pg/mL.
* Evidence of cognitive decline over the last year must be present based on informant observation, medical records, or objective neurocognitive testing.
* Magnetic resonance imaging (MRI) or computed tomography (CT) scan performed within 12 months before screening, with findings consistent with the clinical diagnosis of mild to moderate AD without any other clinically significant comorbid pathologies, especially cerebrovascular lesions. If an MRI or CT scan is unavailable within 12 months before screening, an MRI assessment should be completed, and the findings confirmed before the participant's treatment start (V1).
* Mini-Mental State Examination (MMSE) score of ≥18 and ≤26 at screening.
* Modified Hachinski Ischemic (mHIS) Scale ≤4 unless recent MRI study demonstrates no vascular causes for dementia.
* Use of AChEIs (e.g., donepezil, galantamine, or rivastigmine) is mandatory and treatment must be on a stable dose for at least 3 months prior to baseline
* Adequate vision, hearing, and motor function to comply with testing.
* Ability to swallow size 2 capsules.
* In the opinion of the Investigator is in reasonably good health for 21-week trial participation.
* Trial participants must consent to ApoE genotyping. Their ApoE status may be disclosed to the participant at the Investigator's discretion.
* Must have an informant or trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant (at least 10 hours/week), who is considered reliable by the Investigator in providing support to the participant to ensure compliance with the trial intervention, including the proper and consistent intake of the study medication, who can accompany the participant to trial visits and help with protocol procedures, and who is also able and willing to provide input for completing the caregiver scales and sign the caregiver consent form.
* Male or female aged 50 to 85 years, inclusive at the time of consent.
* Female trial participants must be post-menopausal for at least 2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months prior to screening.
* Male trial participants with partners who are women of childbearing potential (WOCBP) must agree to use a reliable means of contraception (e.g., minimum condom + spermicide) during the trial and 6 months after discontinuing the trial intervention
* Participants who have a clinical diagnosis of AD, which falls into the stages of mild to moderate dementia (Stage 4 to 5) according to the utilized by the NIA-AA 2018 criteria at screening.
* Patients who show CSF biomarker data supporting the diagnosis of AD measured within the last 3 years or patients with a positive Amyloid Pet Scan within the last 3 years or have a test on p-tau217 in plasma indicating brain amyloid positivity will qualify for the study. Plasma pTau217 concentration of ≥ 2.0 pg/mL.
* Evidence of cognitive decline over the last year must be present based on informant observation, medical records, or objective neurocognitive testing.
* Magnetic resonance imaging (MRI) or computed tomography (CT) scan performed within 12 months before screening, with findings consistent with the clinical diagnosis of mild to moderate AD without any other clinically significant comorbid pathologies, especially cerebrovascular lesions. If an MRI or CT scan is unavailable within 12 months before screening, an MRI assessment should be completed, and the findings confirmed before the participant's treatment start (V1).
* Mini-Mental State Examination (MMSE) score of ≥18 and ≤26 at screening.
* Modified Hachinski Ischemic (mHIS) Scale ≤4 unless recent MRI study demonstrates no vascular causes for dementia.
* Use of AChEIs (e.g., donepezil, galantamine, or rivastigmine) is mandatory and treatment must be on a stable dose for at least 3 months prior to baseline
* Adequate vision, hearing, and motor function to comply with testing.
* Ability to swallow size 2 capsules.
* In the opinion of the Investigator is in reasonably good health for 21-week trial participation.
* Trial participants must consent to ApoE genotyping. Their ApoE status may be disclosed to the participant at the Investigator's discretion.
Exclusion Criteria
* Inability to comply with visit schedule or other protocol requirements and failure to perform screening and baseline first treatment visit (V1) assessments.
* Planned start of NMDA receptor antagonist memantine during the trial period (i.e., the next 13 weeks) or use of memantine within the past 4 weeks before screening, unless at a stable dose for at least 8 weeks prior to screening.
* Prior use of anti-beta-amyloid immunotherapy (e.g., Aducanumab, Leqanemab, Donanemab) or administration of anti-amyloid vaccine.
* Enrollment in another investigational clinical trial and, respectively, administration of investigational drug within the previous 3 months small molecules. Previous participation in investigational clinical trials with monoclonal antibodies against amyloid or other anti-beta amyloid immunotherapy and other biologicals.
* Current use of anticholinergics, including trospium within the past 2 weeks before screening.
* Use of the following medications:
1. Long-acting benzodiazepines (e.g., valium), except for sedation prior to screening MRI scans for those participants requiring sedation and should not be administered within 24 hours prior to cognitive testing.
2. Short/medium-acting benzodiazepines (e.g., alprazolam, lorazepam, oxazepam, temazepam) except if used chronically for sleep and on a stable dose for ≥4 weeks prior to screening and throughout the trial. May not be taken within 12 hours prior to cognitive testing.
3. Sedating antihistamines if taken within 12 hours prior to cognitive testing (Non-sedating antihistamines \[e.g., fexofenadine, cetirizine\] are allowed).
4. Anticonvulsants that have significant effects on cognition per the Investigator's opinion and/or anticonvulsants used for treatment of seizures. Anticonvulsants with limited cognitive effects, such as lamotrigine, pregabalin, levetiracetam for the treatment of pain, and other non-epilepsy indications are allowed if, in the opinion of the Investigator, they are not producing sedation or contributing to cognitive impairment. The participant must have been on a stable dose for ≥4 weeks prior to screening and throughout the trial.
5. Antidepressants that may, in the Investigator's opinion, affect the participant's cognition (e.g., tricyclic antidepressants). Mild depression or depressive mood arising in the context of AD are not criteria for exclusion. Use of antidepressants is allowed if at stable doses for ≥4 weeks prior to screening and throughout the trial.
6. Antipsychotics used regularly, except for low doses of atypical antipsychotics (e.g., risperidone, aripiprazole, or quetiapine) if used on an as-needed basis or if used at a stable dose for ≥4 weeks prior to screening and throughout the duration of the trial. The definition of "low doses" should be judged by the Investigator, and the Medical Monitor can be consulted if needed.
7. Prior use of levodopa or anti-Parkinsonian medications including dopaminergic agents, amantadine, selegiline, benztropine, and monoamine oxidase (MAO) inhibitors prescribed for the treatment of Parkinsonism or Parkinson's disease.
8. Use of prescription narcotic medications within 4 weeks prior to screening. After randomization, short-term use of prescription narcotics is allowed for specific situations (e.g., after surgical procedures) and if administered at least 24 hours prior to cognitive testing.
9. Use of drugs with known QT-prolonging effects36, unless used at a stable dose for ≥12 weeks prior to screening and throughout the duration of the trial, and with demonstrated stable QT interval on treatment.
10. Use of any drug of abuse, including but not limited to, amphetamine, cannabis, cocaine, opiate, propoxyphene, methadone, methaqualone, phencyclidine, or barbiturates.
11. Centrally active anti-hypertensive drugs (clonidine, l-methyl DOPA, guanidine, guanfacine, etc.).
* Hospitalization or change of chronic concomitant medication within 4 weeks prior to screening or during screening period.
* Clinical, laboratory or neuro-imaging findings consistent with:
1. Other primary degenerative dementia, (e.g., dementia with Lewy bodies, fronto temporal dementia, Parkinson's disease, Huntington's disease, Creutzfeldt-Jakob's disease, Down's syndrome, etc.).
2. Other neurodegenerative condition (e.g., Parkinson's disease, Amyotrophic Lateral Sclerosis, etc.).
3. Cerebrovascular disease (major infarct, 1 strategic or multiple lacunar infarcts, extensive white matter lesions \>one quarter of the total white matter) based on historical or current CT or MRI.
4. Other CNS diseases (e.g., severe head trauma, tumors, subdural hematoma, or other space-occupying processes, etc.).
5. Seizure disorder, except history of febrile seizures in childhood.
6. Other infectious, metabolic, or systemic diseases affecting the CNS (e.g., syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, serum electrolytes out of normal range, juvenile-onset diabetes mellitus, etc.).
* A current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of active major depression, schizophrenia, or bipolar disorder or are at suicide risk, as determined by meeting any of the following criteria:
1. Suicide attempt within the past 12 months prior to screening.
2. Suicidal ideation as defined by a positive response to questions 4 and 5 on the C-SSRS within 60 days of screening.
* Have a history of substance abuse (based on DSM-IV criteria) within the past 12 months prior to screening, a positive urine drug (due to nonprescription drug) or alcohol test at screening, or use of cannabinoids (prescription or recreational).
* Significant acute or chronic infection at screening including, among others: History of, or positive test result at screening visit for, human immunodeficiency virus (HIV) or known current hepatitis C or hepatitis B virus infection, or positive test result at screening (defined as hepatitis B virus \[HBV\] surface Ag positive or positive HCV with reflex to positive hepatitis C virus \[HCV\] RNA).
* Clinically significant, advanced, or unstable disease that may interfere with primary or secondary variable evaluations, and which may bias the assessment of the clinical or mental status of the trial participant or put the participant at special risk, such as:
1. Respiratory insufficiency.
2. Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within 6 months before screening).
3. Bradycardia (heartbeat \<50/min) or tachycardia (heartbeat \>100/min), confirmed by repeat measurement.
4. Higher degree AV block (Mobitz type II and III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcF-interval (males \>450 msec and females \>470 msec).
5. Uncontrolled hypertension (\>180/95 mm Hg) or hypotension (\<90/60 mm Hg or higher if symptomatic), confirmed by repeat measurement.
* Indication of impaired renal function at screening defined as creatinine clearance ≤60 mL/min according to Chronic Kidney Epidemiology Collaboration (CKD-EPI) formula (confirmed by repeat measurement).
* Indication of uncontrolled diabetes at screening defined by HbA1c \>8.5%.
* Indication of chronic liver disease, liver function test abnormalities, or other signs of hepatic insufficiency (alanine transaminase \[ALT\], aspartate aminotransferase \[AST\], gamma-glutamyl transferase (GGT), or alkaline phosphatase \[ALP\] \>2.5 upper limit of normal \[ULN\]; confirmed by repeat measurement).
* History of pre-malignant or malignant disease. The following exceptions may be made after discussion with the Sponsor:
1. Participants with cancers in remission ≥5 years prior to screening.
2. Participants with a history of excised or treated basal cell or squamous carcinoma of the skin.
3. Participants with localized prostate cancer with treatment cycles that were completed at least 6 months prior to screening.
* Suspected or known allergy to any components of the trial interventions.
* Any condition, which, in the opinion of the Investigator, makes the trial participant unsuitable for inclusion.
* If the trial participant is in any way dependent on the Sponsor or the Investigator or if the trial participant is accommodated in an establishment on a judicial or administrative order.
* Female participants who are pregnant or currently breastfeeding or who plan to become pregnant.
* Male participants with a partner who is pregnant or currently breastfeeding or who plans to become pregnant.
* In case an MRI is needed at screening, contraindications to having a brain MRI (e.g., MRI-incompatible pacemaker, MRI-incompatible aneurysm clips, artificial heart valves, or other metal foreign body; claustrophobia that cannot be medically managed).
* Any contraindication to trospium chloride, including known hypersensitivity to trospium chloride or any of the excipients listed in the SmPC, myasthenia gravis, urinary retention, gastric retention, toxic megacolon, ulcerative colitis or uncontrolled narrow-angle glaucoma.
* Planned start of NMDA receptor antagonist memantine during the trial period (i.e., the next 13 weeks) or use of memantine within the past 4 weeks before screening, unless at a stable dose for at least 8 weeks prior to screening.
* Prior use of anti-beta-amyloid immunotherapy (e.g., Aducanumab, Leqanemab, Donanemab) or administration of anti-amyloid vaccine.
* Enrollment in another investigational clinical trial and, respectively, administration of investigational drug within the previous 3 months small molecules. Previous participation in investigational clinical trials with monoclonal antibodies against amyloid or other anti-beta amyloid immunotherapy and other biologicals.
* Current use of anticholinergics, including trospium within the past 2 weeks before screening.
* Use of the following medications:
1. Long-acting benzodiazepines (e.g., valium), except for sedation prior to screening MRI scans for those participants requiring sedation and should not be administered within 24 hours prior to cognitive testing.
2. Short/medium-acting benzodiazepines (e.g., alprazolam, lorazepam, oxazepam, temazepam) except if used chronically for sleep and on a stable dose for ≥4 weeks prior to screening and throughout the trial. May not be taken within 12 hours prior to cognitive testing.
3. Sedating antihistamines if taken within 12 hours prior to cognitive testing (Non-sedating antihistamines \[e.g., fexofenadine, cetirizine\] are allowed).
4. Anticonvulsants that have significant effects on cognition per the Investigator's opinion and/or anticonvulsants used for treatment of seizures. Anticonvulsants with limited cognitive effects, such as lamotrigine, pregabalin, levetiracetam for the treatment of pain, and other non-epilepsy indications are allowed if, in the opinion of the Investigator, they are not producing sedation or contributing to cognitive impairment. The participant must have been on a stable dose for ≥4 weeks prior to screening and throughout the trial.
5. Antidepressants that may, in the Investigator's opinion, affect the participant's cognition (e.g., tricyclic antidepressants). Mild depression or depressive mood arising in the context of AD are not criteria for exclusion. Use of antidepressants is allowed if at stable doses for ≥4 weeks prior to screening and throughout the trial.
6. Antipsychotics used regularly, except for low doses of atypical antipsychotics (e.g., risperidone, aripiprazole, or quetiapine) if used on an as-needed basis or if used at a stable dose for ≥4 weeks prior to screening and throughout the duration of the trial. The definition of "low doses" should be judged by the Investigator, and the Medical Monitor can be consulted if needed.
7. Prior use of levodopa or anti-Parkinsonian medications including dopaminergic agents, amantadine, selegiline, benztropine, and monoamine oxidase (MAO) inhibitors prescribed for the treatment of Parkinsonism or Parkinson's disease.
8. Use of prescription narcotic medications within 4 weeks prior to screening. After randomization, short-term use of prescription narcotics is allowed for specific situations (e.g., after surgical procedures) and if administered at least 24 hours prior to cognitive testing.
9. Use of drugs with known QT-prolonging effects36, unless used at a stable dose for ≥12 weeks prior to screening and throughout the duration of the trial, and with demonstrated stable QT interval on treatment.
10. Use of any drug of abuse, including but not limited to, amphetamine, cannabis, cocaine, opiate, propoxyphene, methadone, methaqualone, phencyclidine, or barbiturates.
11. Centrally active anti-hypertensive drugs (clonidine, l-methyl DOPA, guanidine, guanfacine, etc.).
* Hospitalization or change of chronic concomitant medication within 4 weeks prior to screening or during screening period.
* Clinical, laboratory or neuro-imaging findings consistent with:
1. Other primary degenerative dementia, (e.g., dementia with Lewy bodies, fronto temporal dementia, Parkinson's disease, Huntington's disease, Creutzfeldt-Jakob's disease, Down's syndrome, etc.).
2. Other neurodegenerative condition (e.g., Parkinson's disease, Amyotrophic Lateral Sclerosis, etc.).
3. Cerebrovascular disease (major infarct, 1 strategic or multiple lacunar infarcts, extensive white matter lesions \>one quarter of the total white matter) based on historical or current CT or MRI.
4. Other CNS diseases (e.g., severe head trauma, tumors, subdural hematoma, or other space-occupying processes, etc.).
5. Seizure disorder, except history of febrile seizures in childhood.
6. Other infectious, metabolic, or systemic diseases affecting the CNS (e.g., syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, serum electrolytes out of normal range, juvenile-onset diabetes mellitus, etc.).
* A current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of active major depression, schizophrenia, or bipolar disorder or are at suicide risk, as determined by meeting any of the following criteria:
1. Suicide attempt within the past 12 months prior to screening.
2. Suicidal ideation as defined by a positive response to questions 4 and 5 on the C-SSRS within 60 days of screening.
* Have a history of substance abuse (based on DSM-IV criteria) within the past 12 months prior to screening, a positive urine drug (due to nonprescription drug) or alcohol test at screening, or use of cannabinoids (prescription or recreational).
* Significant acute or chronic infection at screening including, among others: History of, or positive test result at screening visit for, human immunodeficiency virus (HIV) or known current hepatitis C or hepatitis B virus infection, or positive test result at screening (defined as hepatitis B virus \[HBV\] surface Ag positive or positive HCV with reflex to positive hepatitis C virus \[HCV\] RNA).
* Clinically significant, advanced, or unstable disease that may interfere with primary or secondary variable evaluations, and which may bias the assessment of the clinical or mental status of the trial participant or put the participant at special risk, such as:
1. Respiratory insufficiency.
2. Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within 6 months before screening).
3. Bradycardia (heartbeat \<50/min) or tachycardia (heartbeat \>100/min), confirmed by repeat measurement.
4. Higher degree AV block (Mobitz type II and III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcF-interval (males \>450 msec and females \>470 msec).
5. Uncontrolled hypertension (\>180/95 mm Hg) or hypotension (\<90/60 mm Hg or higher if symptomatic), confirmed by repeat measurement.
* Indication of impaired renal function at screening defined as creatinine clearance ≤60 mL/min according to Chronic Kidney Epidemiology Collaboration (CKD-EPI) formula (confirmed by repeat measurement).
* Indication of uncontrolled diabetes at screening defined by HbA1c \>8.5%.
* Indication of chronic liver disease, liver function test abnormalities, or other signs of hepatic insufficiency (alanine transaminase \[ALT\], aspartate aminotransferase \[AST\], gamma-glutamyl transferase (GGT), or alkaline phosphatase \[ALP\] \>2.5 upper limit of normal \[ULN\]; confirmed by repeat measurement).
* History of pre-malignant or malignant disease. The following exceptions may be made after discussion with the Sponsor:
1. Participants with cancers in remission ≥5 years prior to screening.
2. Participants with a history of excised or treated basal cell or squamous carcinoma of the skin.
3. Participants with localized prostate cancer with treatment cycles that were completed at least 6 months prior to screening.
* Suspected or known allergy to any components of the trial interventions.
* Any condition, which, in the opinion of the Investigator, makes the trial participant unsuitable for inclusion.
* If the trial participant is in any way dependent on the Sponsor or the Investigator or if the trial participant is accommodated in an establishment on a judicial or administrative order.
* Female participants who are pregnant or currently breastfeeding or who plan to become pregnant.
* Male participants with a partner who is pregnant or currently breastfeeding or who plans to become pregnant.
* In case an MRI is needed at screening, contraindications to having a brain MRI (e.g., MRI-incompatible pacemaker, MRI-incompatible aneurysm clips, artificial heart valves, or other metal foreign body; claustrophobia that cannot be medically managed).
* Any contraindication to trospium chloride, including known hypersensitivity to trospium chloride or any of the excipients listed in the SmPC, myasthenia gravis, urinary retention, gastric retention, toxic megacolon, ulcerative colitis or uncontrolled narrow-angle glaucoma.
Minimum Eligible Age
50 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NeuroScios GmbH
UNKNOWN
Sponsor Role
collaborator
NSC-Therapeutics
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manfred Windisch, PhD
Role: STUDY_CHAIR
NSC-Therapeutics GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Graz
Graz, Styria, Austria
Site Status
Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft GmbH
Salzburg, , Austria
Site Status
Zentrum fuer klinische Forschung Dr. I. Schoell GmbH
Bad Homburg, , Germany
Site Status
Universitaetsmedizin Goettingen
Göttingen, , Germany
Site Status
Dynamikos GmbH Institut fuer Studien zur Psychischen Gesundheit
Mannheim, , Germany
Site Status
Rostock University Medical Center
Rostock, , Germany
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Austria
Germany
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J Neurochem. 2012 Jan;120 Suppl 1:22-33. doi: 10.1111/j.1471-4159.2011.07507.x. Epub 2011 Nov 28.
Reference Type
BACKGROUND
Fisher A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics. 2008 Jul;5(3):433-42. doi: 10.1016/j.nurt.2008.05.002.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-518563-35-00
Identifier Type: CTIS
Identifier Source: secondary_id
NSC24001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
NCT00479557
COMPLETED
PHASE2
Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease
NCT00857649
TERMINATED
PHASE3
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00105547
COMPLETED
PHASE3
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
NCT01350362
COMPLETED
PHASE2
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
NCT05469360
RECRUITING
PHASE1
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
NCT03560245
COMPLETED
PHASE2
Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease
NCT03056495
TERMINATED
PHASE1
Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease
NCT02386306
COMPLETED
PHASE1
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
NCT03008161
COMPLETED
PHASE1
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
COMPLETED
PHASE2
Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease
NCT00675090
COMPLETED
PHASE1
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
NCT00874939
TERMINATED
PHASE1
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
NCT00420420
COMPLETED
PHASE2
Bryostatin Treatment of Moderately Severe Alzheimer's Disease
NCT04538066
COMPLETED
PHASE2
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
NCT00141661
COMPLETED
PHASE2
A Phase I Study for Safety and Tolerability of AL002.
NCT03635047
COMPLETED
PHASE1
Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)
NCT00567060
COMPLETED
NA
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
NCT00607308
COMPLETED
PHASE1
Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease
NCT00469456
COMPLETED
PHASE4
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
NCT00006187
TERMINATED
PHASE3
A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD
NCT04498650
COMPLETED
PHASE2
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
NCT03352557
TERMINATED
PHASE2
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
NCT01569516
UNKNOWN
PHASE2
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
NCT00257673
COMPLETED
PHASE2
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
NCT01024660
COMPLETED
EARLY_PHASE1